CanBas Co., Ltd. Stock Price

TSE:4575 Community·JP¥12.0b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

4575 Share Price Performance

JP¥629.00

-541.00 (-46.24%)

JP¥629.00

-541.00 (-46.24%)

JP¥629.00

Wed, 27 May 26

Share Pricen/a

4575 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

CanBas Co., Ltd. Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: -62.73
: 0%
: 0%
: 0%

View Full Analysis

About 4575

Founded: 2000
Employees: 14
CEO: Takumi Kawabe
WebsiteView website: www.canbas.co.jp

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.